drugset
drugset / Trial / NCT01585766

Safety and Tolerability Study of MEDI-551, a B-cell Depleting Agent, to Treat Relapsing Forms of Multiple Sclerosis

NCT01585766 ↗

Phase 1 Completed 56 enrolled MedImmune LLC
RandomizedParallel-groupTriple-blindTreatment

Summary

The purpose of this study is to evaluate the safety and tolerability of ascending intravenous (IV) and subcutaneous (SC) doses of MEDI-551 in adult subjects with relapsing forms of multiple sclerosis (MS).

Timeline

Start
2012-04-24
Primary completion
2015-01-02
Completion
2016-06-20

Drugs

EvaluationDrugModalityDoseRoute
Subject Inebilizumab Monoclonal antibody 30 mg Intravenous
Subject Inebilizumab Monoclonal antibody 60 mg Intravenous
Subject Inebilizumab Monoclonal antibody 100 mg Intravenous
Subject Inebilizumab Monoclonal antibody 300 mg Intravenous
Subject Inebilizumab Monoclonal antibody 600 mg Intravenous

Indications

multiple sclerosis